455 E. MEDICAL CENTER BLVD, HOUSTON, TX
FibroBiologics Enters At The Market Offering Agreement with H.C. Wainwright
Stock Options Granted to Executives at FibroBiologics, Inc.
Annual Report to Security Holders
FibroBiologics Enters At The Market Offering Agreement for $6.15 Million
Compliant with All Nasdaq Listing Requirements
Bylaw Amendment - Quorum Requirement Changed to One-Third Voting Power
Amended material disclosure
FibroBiologics, Inc. Terminates Sublease Agreement with United Fire Group
Amended Annual Report
FY 2024
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement